Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 5, 2011, Pages 518-525

  Geiser, Franziska ^a   Conrad, Rupert ^a   Imbierowicz, Katrin ^a   Meier, Christian ^a   Liedtke, Reinhard ^a   Klingmüller, Dietrich ^b   Oldenburg, Johannes ^a   Harbrecht, Ursula ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Department of Endocrinology   (Germany)

Author keywords

anxiety; coagulation; fibrinolysis; hemostasis; serotonin reuptake inhibitors

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; D DIMER; DOXEPIN; ESCITALOPRAM; FIBRINOGEN; FLUOXETINE; MELPERONE; MIRTAZAPINE; OPIPRAMOL; PERAZINE; PLASMINOGEN ACTIVATOR INHIBITOR; PROMETHAZINE; PROTHROMBIN; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; VON WILLEBRAND FACTOR;

ADULT; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FIBRINOLYSIS; GENERALIZED ANXIETY DISORDER; HUMAN; MALE; PANIC; PARTIAL THROMBOPLASTIN TIME; POSTTRAUMATIC STRESS DISORDER; SOCIAL PHOBIA;

ADULT; ANXIETY; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BODY MASS INDEX; DEPRESSION; FEMALE; FIBRINOLYSIS; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 80051965764     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02241.x     Document Type: Article

References (42)

1. Geiser F, Meier C, Wegener I, et al,. Association between anxiety and factors of coagulation and fibrinolysis. Psychother. Psychosom. 2008; 77: 377-383.
2. Roest AM, Martens EJ, de Jonge P, Denollet J,. Anxiety and risk of incident coronary heart disease: a meta-analysis. J. Am. Coll. Cardiol. 2010; 56: 38-46.
3. Kubzansky LD, Kawachi I, Weiss S, Sparrow D,. Anxiety and coronary heart disease: a synthesis of epidemiological, psychological, and experimental evidence. Ann. Behav. Med. 1998; 20: 47-58. (Pubitemid 29071466)
4. Von Känel R, Mills PJ, Fainman C, Dimsdale JE,. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom. Med. 2001; 63: 531-544. (Pubitemid 32695133)
5. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ,. WFSBP Task force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 2002; 3: 171-199.
6. Petersen T, Andreotti CF, Chelminski I, Young D, Zimmerman M,. Do comorbid anxiety disorders impact treatment planning for outpatients with major depressive disorder? Psychiatry Res. 2009; 169: 7-11.
7. Pollock BG, Laghrissi-Thode F, Wagner WR,. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J. Clin. Psychopharmacol. 2000; 20: 137-140. (Pubitemid 30202354)
8. Menys VC, Smith CC, Lewins P, Farmer RD, Noble MI,. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin. Sci. (Lond.) 1996; 91: 87-92. (Pubitemid 26238301)
9. Halperin D, Reber G,. Influence of antidepressants on hemostasis. Dialogues Clin. Neurosci. 2007; 9: 47-59. (Pubitemid 46607130)
10. Looper KJ,. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics 2007; 48: 1-9. (Pubitemid 46048019)
11. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B,. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther. 2000; 68: 435-442.
12. Lederbogen F, Weber B, Colla M, Heuser H, Deuschle M, Dempfle CE,. Antidepressant treatment and global tests of coagulation and fibrinolysis. J. Clin. Psychiatry 2001; 62: 130. (Pubitemid 32199875)
13. Lainé-Cessac P, Shoaay I, Garre JB, Glaud V, Turcant A, Allain P,. Study of haemostasis in depressive patients treated with fluoxetine. Pharmacoepidemiol. Drug Saf. 1998; 7 (Suppl. 1): S54-S57. (Pubitemid 28343429)
14. Alderman CP, Seshadri P, Ben-Tovim DI,. Effects of serotonin reuptake inhibitors on hemostasis. Ann. Pharmacother. 1996; 30: 1232-1234. (Pubitemid 26367441)
15. Berk M, Jacobson BF, Hurly E,. Fluoxetine and hemostatic function: a pilot study. J. Clin. Psychiatry 1995; 56: 14-16.
16. Bang NU,. Acquired abnormalities of platelet function (letter to the editor). N. Engl. J. Med. 1991; 324: 1672.
17. Wittchen HU, Zaudig M, Fydrich T,. SKID: Strukturiertes Klinisches Interview Für DSM-IV: Achse I und II. Hogrefe, Göttingen, 1997.
18. Harvey AT, Rudolph RL, Preskorn SH,. Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 2000; 57: 503-509. (Pubitemid 30257265)
19. Laux L, Glanzmann P, Schaffner P, Spielberger CD,. Das State-Trait-Angstinventar. Beltz Test, Weinheim, 1981.
20. Hautzinger M, Bailer M,. Die Allgemeine Depressionsskala. Hogrefe, Göttingen, 1993.
21. Radloff LS,. The CES-D scale: a self report depression scale for research in the general population. Appl. Psychol. Meas. 1977; 1: 385-401.
22. von Känel R,. Platelet hyperreactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence? Acta Psychiatr. Scand. 2004; 110: 163-177. (Pubitemid 39120319)
23. Chrusciel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH,. Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med. Sci. Monit. 2009; 15: RA203-RA208.
24. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC,. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch. Intern. Med. 2004; 164: 2367-2370. (Pubitemid 39532249)
25. Serebruany VL,. Selective serotonin reuptake inhibitors and increased bleeding: are we missing something? Am. J. Med. 2006; 119: 113-116. (Pubitemid 43151473)
26. Schlienger RG, Fischer LM, Jick H, Meier CR,. Current use of serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004; 27: 1157-1165. (Pubitemid 39647855)
27. Serebruany VL, Glassman AH, Malinin AI, et al,. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-944. (Pubitemid 37048222)
28. Writing Committee for the ENRICHD Investigators. The Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106-3116.
29. Fisar Z, Kalisova L, Paclt I, Anders M, Vevera J,. Platelet serotonin uptake in drug-naive depressive patients before and after treatment with citalopram. Psychiatry Res. 2008; 161: 185-194.
30. Von Känel R, Mills PJ, Ziegler MG, Dimsdale JE,. The effect of β2-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am. Heart J. 2002; 144: 68-72. (Pubitemid 34734757)
31. George JN, Shattil SJ,. The clinical importance of acquired abnormalities of platelet function. N. Engl. J. Med. 1991; 324: 27-39.
32. Bottlender R, Dobmeier P, Möller HJ,. The effect of selective serotonin-reuptake inhibitors in blood coagulation. Fortschr. Neurol. Psychiatr. 1998; 66: 32-35.
33. Kremer HP, Goekoop JG, van Kempen GM,. Clinical use of the determination of serotonin in whole blood. J. Clin. Psychopharmacol. 1990; 10: 83-87. (Pubitemid 20137603)
34. Hoeksema TJG, Goekoop JG, van Kempen GM,. Effects of fluvoxamine on whole blood serotonin and platelet number. J. Clin. Psychopharmacol. 1993; 13: 75-76. (Pubitemid 23030365)
35. Skop BP, Brown TM,. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-16. (Pubitemid 26021814)
36. Urano T, Malysko J, Takada Y, Takada A,. Close relationships between serotonergic and fibrinolytic systems revealed by a monoamine oxidase inhibitor treatment in rats. Haemostasis 1995; 25: 277-282.
37. van Zyl LT, Lesperance F, Frasure-Smith N, et al,. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J. Thromb. Thrombolysis 2009; 27: 48-56.
38. Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M,. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005; 106: 4167-4175. (Pubitemid 41775923)
39. Carvalho LA, Pariante CM,. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 2008; 11: 411-424.
40. Fujimura H, Altar CA, Chen R, et al,. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 2002; 87: 728-734. (Pubitemid 34302963)
41. Yoshimura R, Ikenouchi-Sugita A, Hori H, et al,. Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder. Seishin Shinkeigaku Zasshi 2010; 112: 982-985 (in Japanese with English abstract).
42. Lorgis L, Amoureux S, de Maistre E, et al,. Serum brain-derived neurotrophic factor and platelet activation evaluated by soluble P-selectin and soluble CD-40-ligand in patients with acute myocardial infarction. Fundam. Clin. Pharmacol. 2010; 24: 525-530.